Zobrazeno 1 - 10
of 47
pro vyhledávání: '"David F. Claxton"'
Autor:
Jeff Sivik, Chenchen Zhao, Natthapol Songdej, Todd D. Schell, Witold B. Rybka, David F. Claxton, Seema Naik, Hong Zheng, Ming Wang, W. Christopher Ehmann, Bei Jia, Raymond J. Hohl, Hui Zeng, Shin Mineishi
Publikováno v:
British Journal of Haematology
Summary Decitabine is a DNA‐hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. Although effective, the complete response rate to decitabine
Autor:
John C. Grecula, Michaela Liedtke, Kristina Laumann, Guido Marcucci, Richard A. Larson, Wendy Stock, Noreen Fulton, Mark R. Litzow, Selina M. Luger, Martin S. Tallman, Jeffrey A. Bogart, Greg Malnassy, Krzysztof Mrózek, Richard Stone, Frederick R. Appelbaum, Matthew C. Foster, Edy Parker, Anjali S. Advani, Ben L. Sanford, Jun Yin, Charles G. Mullighan, Susan Geyer, Elisabeth Paietta, Richard C. Harvey, Harry P. Erba, Clara D. Bloomfield, Cheryl L. Willman, David F. Claxton
Publikováno v:
Blood. 133:1548-1559
Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address th
Autor:
Elisabeth Paietta, Zhuoxin Sun, Martin S. Tallman, Neil E. Kay, Natalie S. Callander, Sanford Kempin, Rhett P. Ketterling, Gordan Srkalovic, David F. Claxton, Gerald Gross, Joseph J. Mazza, Olga Frankfurt, Joel N. Saltzman
Publikováno v:
Acta Haematol
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from salvage chemoimmunotherapy (CIT). To explore further the use of CIT in the pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utili
Autor:
Shin Mineishi, Christopher Ehmann, David F. Claxton, Valerie I. Brown, Neal Shah, Witold B. Rybka, Joseph Mierski, Gina Mackey, Hong Zheng, Myles Nickolich, Seema Naik, Kentaro Minagawa, Baldeep Wirk, Robert J. Greiner, Kevin Rakszawski, Brooke Silar
Publikováno v:
Annals of hematology. 100(10)
Acute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (alloSCT) remains a major therapeutic challenge. While patients with longer remission after initial alloSCT are recommended to receive cell therapy (CT) such as 2ndalloSCT or
Autor:
Amit Verma, Selina M. Luger, Zhuoxin Sun, Puneet S. Cheema, Jaroslaw P. Maciejewski, Martin S. Tallman, Mark R. Litzow, David F. Claxton, Jessica K. Altman, Rami S. Komrokji, John M. Bennett, Alan F. List, Kathy L. McGraw, Ryan J. Mattison, Charles A. Schiffer, Andrew S. Artz, Timothy R. Wassenaar
Publikováno v:
J Clin Oncol
PURPOSE Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b527e937e93c76976bde4e0ca2a12342
https://europepmc.org/articles/PMC8274743/
https://europepmc.org/articles/PMC8274743/
Autor:
Todd E. Fox, Mark Kester, Hong Gang Wang, Shantu Amin, Charyguly Annageldiyev, Gemma Fabriàs, Jennifer M. Pearson, David J. Feith, Dhimant Desai, Thomas P. Loughran, José Luis Abad, Su Fern Tan, Myles C. Cabot, David F. Claxton, Arati Sharma
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Mol Cancer Res
instname
Mol Cancer Res
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation of immature myeloid cells in the blood and bone marrow. The 5-year survival rate is approximately 25%, and recent therapeutic developments have yielded little survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1bdd7205bbbd915f8f5818c777254c
http://hdl.handle.net/10261/212229
http://hdl.handle.net/10261/212229
Autor:
Ruchi J Desai, Andry Van de Louw, Michael G. Bayerl, David F. Claxton, Coursen Schneider, Cinda Boyer
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 196:1077-1080
Autor:
Raoul Tibes, Stan Gill, Chaofeng Liu, Christoph Röllig, Stephen A. Strickland, Joseph G. Jurcic, Stuart L. Goldberg, Maria R. Baer, Alexander E. Perl, Alexander I. Spira, Andreas Neubauer, Gary J. Schiller, Mark R. Litzow, Richard A. Larson, Catherine C. Smith, Jessica K. Altman, Harry P. Erba, Mark J. Levis, Erkut Bahceci, Giovanni Martinelli, Robert K. Stuart, Eunice S. Wang, Jorge E. Cortes, David F. Claxton, Celalettin Ustun, Ellen K. Ritchie
Publikováno v:
The Lancet. Oncology, vol 18, iss 8
The Lancet. Oncology
The Lancet. Oncology
Summary Background Internal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukaemia
Autor:
Sunita D. Nasta, Jakub Svoboda, Pavel Kiselev, Tatyana Feldman, Paul M. Barr, Daniel Porter, Jeffrey J. Pu, Nicole Lamanna, David F. Claxton, Clive S. Zent, Chadi Nabhan, Alison R. Sehgal, Gurbakhash Kaur, Andrew M. Evens, Spencer Henick Bachow, Anthony R. Mato, Bruce D. Cheson, Andre Goy, Lauren E. Strelec, Chaitra S. Ujjani, Daniel J. Landsburg, Alexandra Vandegrift, Stephen J. Schuster, Danielle M. Fitzpatrick, Brian T. Hill, Alan P Skarbnik, Christina Howlett
Publikováno v:
Blood. 128:2199-2205
B-cell receptor kinase inhibitor (KI) therapy represents a paradigm shift in chronic lymphocytic leukemia (CLL) management, but data on practice patterns after KI discontinuation and optimal sequencing are limited. We conducted a multicenter, retrosp
Autor:
David F. Claxton, Junjia Zhu, Jeffrey J. Pu, Michael G. Bayerl, Joyson Poulose, Jozef Malysz, Julie Fanburg-Smith
Publikováno v:
Br J Haematol